Alcidion enters $1M partnership with UK hospitals NHS trust

|

Published 21-MAR-2019 11:09 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alcidion Group Limited (ASX:ALC) has been selected as strategic solution partner for Brighton and Sussex University Hospitals NHS Trust in the UK, a contract valued at £574,000 (~A$1.03 million) over five years.

Brighton and Sussex University Hospitals NHS Trust selected Alcidion via a competitive tender process to implement its Patientrack software to improve patient safety and support clinicians in delivering better care.

Patientrack is being used widely by NHS hospitals to capture vital signs and other patient risk factors electronically – at the bedside – improving the timeliness and effectiveness of patient monitoring and improving clinical workflow. Patientrack also uses data analytics to provide doctors and nurses with early warning signs when patients are at risk.

The Trust has an ambitious “best of breed” ICT strategy to support its continuous process of improvement leading to measurable improvements for patients and staff. It has four hospitals, employs approximately 8,200 staff, and delivers specialist and tertiary services for patients from across the south east of England and is also the Major Trauma Centre for the region.

The Trust has a long-term approach to transforming hospital service for the better called the “Patient First Improvement System”, which aims to empower front line staff by equipping them with new tools, methods and a structured process that leads to measurable improvements for patients and staff.

Central to this transformation is the Trust’s role as an academic centre, being a provider of high-quality teaching, and a host hospital for cutting edge research and innovation. On this, it works in partnership with Brighton and Sussex Medical School, Health Education England, Kent, Surrey and Sussex Postgraduate Deanery and the Universities of Brighton and Sussex.

Ian Arbuthnot, the Trust’s director of information management and technology said: ‘Following a thorough selection process, we are very pleased to be working with Alcidion to implement its world-class mobile technology software solution across our hospitals.

“Alcidion’s Patientrack product will provide our clinicians with a solution that allows them to capture patients’ vital signs, automatically calculate the NHS’s NEWS2 (National Early Warning Score) and alert clinicians to deteriorating patients, through mobile devices.

“The system will also deliver a range of patient assessments for conditions such as Sepsis, and Acute Kidney Injury and many more that will reduce the burden of paperwork and deliver real-time information in an integrated patient view at the point of care’.

Alcidion’s Managing Director, Kate Quirke said: “We’re delighted to welcome Brighton and Sussex University Hospitals NHS Trust as a new client and partner. To have another NHS Trust contract with us further solidifies our position as one of the leading suppliers of e-observations and clinical documentation solutions and it is very pleasing to be an integral part of the digital transformation program taking place across the NHS.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X